1. Exploring the Impact of a 7-Week Heart Rate Variability Biofeedback Protocol on Skin Severity, Quality of Life, and Mental Health in a Proof-of-Concept Pre-Post Trial of Individuals with Psoriasis.
- Author
-
Jaehwa Park, Sarah, Fox, Devon, Lee Young, Roth, Maya, and Khamba, Baljit
- Subjects
COMPETENCY assessment (Law) ,PSORIASIS treatment ,ANXIETY prevention ,PSYCHOPHYSIOLOGY ,ACADEMIC medical centers ,STATISTICAL hypothesis testing ,KETAMINE ,PILOT projects ,CLINICAL trials ,QUESTIONNAIRES ,BIOFEEDBACK training ,SEVERITY of illness index ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,MIND & body therapies ,HEART beat ,CONTROL groups ,PRE-tests & post-tests ,BREATHING exercises ,YOGA ,QUALITY of life ,MEDITATION ,PSYCHOLOGICAL stress ,REGRESSION analysis ,EVALUATION - Abstract
Background: Psoriasis often coexists with psychiatric disorders and decreased quality of life (QoL), with treatments commonly overlooking the psychological impact of the disease. Heart rate variability biofeedback (HRVB) may offer a mind-body solution by providing real-time feedback on autonomic functions, teaching individuals to manage stress via controlled breathing. Objective: To examine the impact of a 7-week HRVB protocol on skin severity (SS), QoL, and mental health (MH) in individuals with psoriasis and determine the sustainability of any outcomes post-intervention. Methods: A single-arm, proof-of-concept pre-post trial was conducted at Bastyr University Clinic in San Diego, CA. Five individuals were recruited, screened, and underwent a 7-week HRVB protocol. Assessments included SS through the Psoriasis Area and Severity Index (PASI-P and PASI-C), QoL via the Cardiff Dermatology Life Quality Index (DLQI), and MH using the Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9). Data collection points were baseline, post-protocol, and 1-month follow-up. Results: Notable improvements were observed between baseline and post-protocol for PASI-P, DLQI, and GAD-7. A significant change remained for GAD-7 between baseline and follow-up. No major differences were identified for PASI-C and PHQ-9 across any timeframe, and other scales remained consistent between post-protocol and follow-up. Conclusion: HRVB showed promise in enhancing perceived SS, QoL, and anxiety over 7 weeks. Further studies should expand participant numbers and diversify initial scores, comparing HRVB with a control group. Trial registration: ClinicalTrials.gov NCT05506644, retrospectively registered on 16 August 2022. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF